Pesquisa | SciELO

ABSTRACT The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL.

https://doi.org/10.1016/j.htct.2021.09.003

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Perini, Guilherme Fleury

; Fischer, Thais

; Gaiolla, Rafael Dezen

; Rocha, Talita Bueno

; Bellesso, Marcelo

; Teixeira, Larissa Lane Cardoso

; Delamain, Marcia Torresan

; Scheliga, Adriana Alves de Souza

; Ribeiro, Glaciano Nogueira

; Vaz Neto, Jorge

; Baiocchi, Otávio Cesar Carvalho Guimaraes

; Abdo, André Neder Ramires

; Arrais-Rodrigues, Celso

; Fogliatto, Laura M.

; Bigni, Ricardo de Sá

; Schaffel, Rony

; Biasoli, Irene

; Pereira, Juliana

; Nabhan, Samir Kanaan

; Souza, Cármino Antônio de

; Chiattone, Carlos Sérgio

Hematology, Transfusion and Cell Therapy

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2020, Volume 42 Nº 2 Páginas 103 - 110

Resumo: En | Texto: En | PDF: En

ABSTRACT: The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients.

https://doi.org/10.1016/j.htct.2020.04.002 435 downloads

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Rocha, Talita Máira Bueno da Silveira da

; Fortier, Sergio Costa

; Fischer, Thais Rodrigues da Cunha

; Perini, Guilherme Fleury

; Gaiolla, Rafael Dezen

; Fogliatto, Laura

; Delamain, Marcia Torresan

; Costa, Andressa Fragoso da

; Castro, Nelson Siqueira de

; Barretos, Wolney Gois

; Souza, Cármino Antonio de

; Buccheri, Valéria

; Chiattone, Carlos Sérgio

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Set 2017, Volume 39 Nº 3 Páginas 216 - 222

Resumo: En | Texto: En | PDF: En

Abstract Background Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the results on the compassionate use of everolimus in a group of patients who were monitored at nine different centers in Brazil. Methods A 10-mg oral dose of everolimus was given to each patient daily. Response time was evaluated from the beginning of medication use until loss of response, toxicity or medical decision to cease treatment. Results Thirty-three patients were evaluated. The median age at the beginning of medication administration was 29 years. Patients had received a median of five prior therapies. Overall response rate was 45.4%, with 13 patients achieving partial response, two achieved clinical response, 14 remained with stable disease, two had disease progression, and two were not evaluated. Patients received a median of 14 cycles. Progression-free survival was nine months, and overall survival was estimated to be 36 months. Three patients used the medication for more than four years. The most frequently reported adverse events were thrombocytopenia and hypercholesterolemia. Three patients had pulmonary toxicity. Grade III and IV adverse events occurred in 39% of the patients. Conclusion Everolimus was found to provide a response in a group of patients with refractory or relapsed Hodgkin's lymphoma who had adequate tolerability to the drug.

https://doi.org/10.1016/j.bjhh.2017.03.008 674 downloads

Fusariose disseminada com endoftalmite em paciente com neoplasia hematológica
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Perini, Guilherme Fleury

; Camargo, Luis Fernando Aranha

; Lottenberg, Claudio Luiz

; Hamerschlak, Nelson

einstein (São Paulo)

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Dez 2013, Volume 11 Nº 4 Páginas 545 - 546

Resumo: Pt | Texto: Pt | PDF: Pt

3104 downloads

Primary central nervous system lymphoma: what a neurologist/neurosurgeon should know?
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Perini, Guilherme Fleury

; Campregher, Paulo Vidal

; Santos, Fabio Pires de Souza

; Hamerschlak, Nelson

Arquivos de Neuro-Psiquiatria

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Abr 2013, Volume 71 Nº 4 Páginas 254 - 257

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

Linfoma primário do sistema nervoso central é uma doença rara, com prognóstico ruim. Neurologistas e neurocirurgiões devem estar familiarizados com os aspectos do diagnóstico, características biológicas e do manuseio inicial dos pacientes. A abordagem correta desses pacientes é essencial para obter melhores resultados.

Primary central nervous system lymphoma is a rare disease, with bad prognosis. Neurologists and neurosurgeons should be familiar with the diagnostic,and biologic features, as well as the initial management of patients. A correct approach to these patients is mandatory for a better outcome.

https://doi.org/10.1590/0004-282X20130011 6195 downloads

Leucemia de células plasmocitárias
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Souza, Clarissa Lima e Moura de

; Perini, Guilherme Fleury

; Hamerschlak, Nelson

; Silveira, Paulo Augusto Achucarro

einstein (São Paulo)

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Mar 2013, Volume 11 Nº 1 Páginas 132 - 132

Resumo: Pt | Texto: Pt | PDF: Pt

8938 downloads

Not all that shines is cancer: pulmonary cryptococcosis mimicking lymphoma in [(18)] F fluoro-2-deoxy-D-glucose positron emission tomography
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Hamerschlak, Nelson

; Pasternak, Jacyr

; Wagner, Jairo

; Perini, Guilherme Fleury

einstein (São Paulo)

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Dez 2012, Volume 10 Nº 4 Páginas 502 - 504

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

Relato de caso de criptococose pulmonar mimetizando linfoma num exame de tomografia por emissão de pósitrons (PET-scan). Homem de 62 anos com resolução completa, ao PET-scan, de seu linfoma não Hodgkin de células B, lesões abdominais e pulmonares, após três ciclos de quimioterapia baseada em ritoximabe (R-CHOP). Entretanto, o mesmo exame mostrou também novos nódulos pulmonares, sugestivos de lesões do linfoma. Granuloma inflamatório crônico foi observado no exame anatomopatológico, com estruturas circulares compatíveis com fungo. Cultura revelou Cryptococcus neoformans. As lesões desapareceram após 6 semanas de fluconazol, e o paciente pôde continuar a quimioterapia sem complicações infecciosas.

We report of a case of pulmonary cryptococcosis mimicking lymphoma in a positron emission tomography (FDG-PET) scan. A 62-year old man with diffuse large B-cell lymphoma had complete resolution of abdominal and pulmonary lesions after three cycles of rituximab-based chemotherapy (R-CHOP). However, FDG-PET showed new pulmonary nodules, suggesting active lymphoma. Chronic inflammatory granuloma was seen in the histopathological exam, with round-shaped structures compatible with fungus, later identified as Cryptococcus neoformans on culture. The lesions disappeared after 6 weeks of fluconazole therapy, and the patient could continue chemotherapy without further infectious complications.

22761 downloads

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Campregher, Paulo Vidal

; Santos, Fábio Pires de Souza

; Perini, Guilherme Fleury

; Hamerschlak, Nelson

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2012, Volume 34 Nº 2 Páginas 150 - 155

Resumo: En | Texto: En | PDF: En

Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia. Myeloproliferative neoplasms are caused, as any other malignancy, by genetic defects that culminate in the neoplastic phenotype. In the past six years, since the identification of JAK2V617F, we have experienced a substantial increase in our knowledge about the genetic mechanisms involved in the genesis of myeloproliferative neoplasms. Mutations described in several genes have revealed a considerable degree of molecular homogeneity between different subtypes of myeloproliferative neoplasms. At the same time, the molecular differences between each subtype have become clearer. While mutations in several genes, such as JAK2, myeloproliferative leukemia (MPL) and LNK have been validated in functional assays or animal models as causative mutations, the roles of other recurring mutations in the development of disease, such as TET2 and ASXL1 remain to be elucidated. In this review we will examine the most prevalent recurring gene mutations found in myeloproliferative neoplasms and their molecular consequences.

https://doi.org/10.5581/1516-8484.20120035 1933 downloads Citado 2 vezes em SciELO

10.

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Perini, Guilherme Fleury

; Santos, Fabio Pires de Souza

; Esteves, Iracema

; Nascimento, Claudia Mac-Donald Bley do

; Rodrigues, Morgani

; Assis, Reijane Alves de

; Helman, Ricardo

; Kutner, Jose Mauro

; Ribeiro, Andreza Alice Feitosa

; Hamerschlak, Nelson

einstein (São Paulo)

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2011, Volume 9 Nº 2 Páginas 190 - 195

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

Objetivo: Analisar a evolução de pacientes tratados com gemtuzumabe ozogamicina combinado à terapêutica convencional no Hospital Israelita Albert Einstein. Métodos: 14 pacientes que tinham alto risco (leucemia secundária, citogenética desfavorável e doença refratária) foram tratados com gentuzumabe ozogamicina associado à terapêutica convencional, e sua evolução foi analisada por meio de seus prontuários médicos. Resultados: A taxa total de resposta foi de 58%, com 43% chegando a resposta completa, em acompanhamento médio de 11 meses, e três meses com intervalo de sobrevivência livre. Foram a óbito 11 pacientes, 6 deles por leucemia mieloide aguda. Somente quatro pacientes apresentaram graus 3 a 4 de toxicidade e apenas um paciente teve síndrome de obstrução sinusoidal após transplante de medula. Conclusão: Gemtuzumabe ozogamicina associado à terapêutica quimioterápica convencional é um tratamento factível em pacientes com leucemia mieloide aguda. Contudo, novos estudos são necessários para esclarecer qual o subgrupo de pacientes que pode se beneficiar desse tratamento.

Objective: To analyze the outcome of patients treated with gemtuzumab ozogamycin combined with conventional therapy treated at Hospital Israelita Albert Einstein. Methods: 14 patients who had high risk features (secondary leukemia, unfavorable cytogenetics, and refractory disease) were treated with gemtuzumab ozogamycin combined with conventional therapy and their outcome was analysed by reviewing their medical records. Results: Overall response rate was 58%, with 43% achieving complete response, with a median follow-up of 11 months, event-free survival was 3 months. Eleven patients died, 6 of them due to refractory acute myeloid leukemia. Only four patients presented with grade 3 to 4 toxicities and only one patient had sinusoidal obstruction syndrome after bone marrow transplant. Conclusion: gemtuzumab ozogamycin combined with chemotherapy is a feasible treatment regimen in acute myeloid leukemia patients. However, further studies are necessary to clarify which subgroup of patients may beneft from this treatment.

https://doi.org/10.1590/s1679-45082011ao1987 2092 downloads

11.

Hodgkin's disease and pregnancy: case series and proposal for treatment protocol
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Kassab, Carolina

; Perini, Guilherme Fleury

; Bollmann, Patrícia Weinschenker

; Kerbauy, Fabio Rodrigues

; Hamerschlak, Nelson

einstein (São Paulo)

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2011, Volume 9 Nº 2 Páginas 216 - 219

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

O pico de incidência do linfoma de Hodgkin coincide com a idade fértil feminina, sendo atualmente a quarta neoplasia mais diagnosticada na gravidez. Entretanto, não existe consenso na literatura sobre como tratar essas pacientes, devido aos riscos da quimioterapia tanto para a gestante quando para o feto. Relatamos três casos de gestantes acometidas por linfoma de Hodgkin e realizamos a revisão de literatura com o objetivo sugerir um protocolo de tratamento para essas pacientes.

The peak frequency of Hodgkin's disease convergesmatches with women of reproductive fertility age. Currently, this disease is the fourth more diagnosed neoplasia during pregnancy. In addition, there is no consensus in the literature on how to treat pregnant women because of the risks of chemotherapy for mothers and for fetuses. We report three cases of pregnant women with Hodgkin's disease. A review of the literature was made aiming to suggest a protocol to treat these patients.

https://doi.org/10.1590/s1679-45082011rc1992 5859 downloads

12.

Acute cerebral infarction in watershed distribution in a patient with hypereosinophilic syndrome
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Perini, Guilherme Fleury

; Kassab, Carolina

; Bley, Claudia

; Monzillo, Paulo Hélio

; Thomaz, Rodrigo Barbosa

; Hamerschlak, Nelson

Arquivos de Neuro-Psiquiatria

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Jun 2009, Volume 67 Nº 2b Páginas 510 - 512

Resumo: En | Texto: En | PDF: En

5465 downloads

13.

Smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia from other B-cell chronic lymphoprolipherative diseases
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Matos, Daniel M.

; Perini, Guilherme

; Kruzich, Carlos

; Rego, Eduardo M.

; Falcão, Roberto P.

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2009, Volume 31 Nº 5 Páginas 333 - 336

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

As sombras nucleares têm sido classicamente associadasà leucemia linfocítica crônica (LLC), embora possam ser encontradas nos esfregaços do sangue periférico de outras doenças linfoproliferativas B crônicas (DLBC). Nesse estudo, nós investigamos se a porcentagem de sombras nucleares nos esfregaços do sangue periférico pode ser utilizada na prática clínica da hematologia para diferenciar a LLC das outras DLBC. Foram analisados os esfregaços do sangue periférico de 63 pacientes com o diagnóstico de LLC e 62 com outras DLPC. Trezentas células, entre células linfoides e sombras nucleares, foram contadas em cada esfregaço. A comparação da porcentagem de sombras nucleares entre os dois grupos foi realizada e, subsequentemente, foram fixados 5 cut-offs de mais de 10%, 20%, 30%, 40% e 50% de sombras nucleares com o propósito de definir um caso como "positivo para sombras nucleares" e verificar se havia diferenças entre a LLC e as outras DLBC. A porcentagem das sombras nucleares em pacientes com LLC (mediana 26%, 4%-86%) foi maior do que em pacientes com DLBC (mediana 14%, 1%-64%). Entretanto, nenhum dos cut-offs testados apresentou valores apropriados de sensibilidade, especificidade e valor preditivo positivo para distinguir os dois grupos. Desde queé necessário se dispor de um único valor de cut-off com alta sensibilidade, especificidade e valor preditivo positivo para inferir o diagnóstico de CLL na prática clínica, conclui-se que as sombras nucleares não são úteis para diferenciar a LLC das outras DLBC.

Smudge cells has been classically associated with chronic lymphocytic leukemia (CLL), but they are found in peripheral blood tests for other chronic B-cell lymphoproliferative diseases (CLD). We investigated whether the percentage of smudge cells in peripheral blood smears can be used in the clinical practice to differentiate CLL from other B-cell CLD. The peripheral blood smears of 63 patients with the diagnosis of CLL and 62 with other B-cell CLD were analyzed. Three hundred cells (both lymphoid cells and smudge cells) were counted for each peripheral blood smear. A comparison of the percentage of smudge cells between the two groups was performed and, subsequently, 5 cut-off values were fixed (10%, 20%, 30%, 40% and 50% of smudge cells) with the aim of defining cases as "positive" or "negative" for smudge cells and verifying whether there are any differences between CLL and the other B-cell CLD. The percentage of smudge cells in patients with CLL (median 26%, 4%-86%) was higher than in patients with B-cell CLD (median 14%, 1%-64%). However, none of the cut-off values tested presented suitable values of sensitivity, specificity and positive predictive value to separate the two groups. As it is necessary to have a single cut-off value with high sensitivity, specificity and positive predictive value to infer the diagnosis of CLL in the clinical practice, we concluded that smudge cells are not fitting to differentiate CLL from other B-cell CLD.

15982 downloads

14.

Bacteremia possibly caused by Curtobacterium spp found in a blood culture from a central venous line of a pediatric leukemia patient who underwent bone marrow transplantation
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Viana-Niero, Cristina

; Perini, Guilherme F.

; Kassab, Carolina

; Martino, Marinês D. V.

; Pasternak, Jacyr

Revista Brasileira de Hematologia e Hemoterapia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

2009, Volume 31 Nº 3 Páginas 205 - 206

Resumo: En | Texto: En | PDF: En

1232 downloads

15.

Síndrome Pré-Menstrual e Desempenho Escolar
Facebook Twitter

Outras redes sociais
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Outras redes

Métricas
- SciELO Analytics

Approbato, Mário Silva

; Silva, Carolina Dias de Araújo e

; Perini, Guilherme Fleury

; Miranda, Tatiana Granzotto

; Fonseca, Thatiany Dias

; Freitas, Verônica Cândido de

Revista Brasileira de Ginecologia e Obstetrícia

Métricas do periódico
- Sobre o periódico
- SciELO Analytics

Ago 2001, Volume 23 Nº 7 Páginas 459 - 462

Resumo: Pt En | Texto: Pt En | PDF: Pt | PDF: En

Objetivos: comparar o desempenho em provas das alunas com e sem síndrome de tensão pré-menstrual (SPM) e de alunas com SPM dentro e fora do período pré-menstrual. Métodos: estudo com desenho antes-depois (quasi-experimental), ao qual se acrescentou um grupo controle sem SPM de 40 alunas. Foram avaliadas 40 alunas de 2º grau e curso pré-vestibular com SPM. Para isso, aplicou-se um questionário padronizado. As avaliações das alunas foram divididas, de acordo com os escores obtidos nos questionários, em três grupos: A) grupo SPM com avaliação durante o período pré-menstrual; B) grupo SPM com avaliação fora do período pré-menstrual; C) controle (sem SPM). Foram analisadas e comparadas as notas em provas de física e matemática dos grupos com e sem SPM pelo método estatístico de Mann-Whitney e as do grupo com SPM dentro e fora do período pré-menstrual pelo teste do sinal. Resultados: dos 4438 questionários aplicados, foram selecionados os de 29 pacientes com SPM e de 29 controles. Comparando-se a mediana das notas das alunas com SPM dentro e fora do período, não houve diferença significativa. Também não houve diferença entre as notas do grupo SPM e controle. Quanto aos escores, também não houve diferença dentro e fora do período, no grupo SPM. Conclusão: a SPM não alterou significativamente as notas ou os escores das alunas em estudo.

Purpose: to compare the performance in tests between students with and without premenstrual syndrome (PMS), and between students with PMS in and outside the premenstrual period. Methods: the present study had a before-after design (quasi-experimental), to which 40 control patients without PMS were added. A total of 40 students from high school and courses for admission to the University were evaluated using, a standardized questionnaire. The students were divided, according to the scores obtained, into three groups: A) PMS group in the premenstrual period; B) PMS group outside the premenstrual period; C) control group (no PMS). The marks obtained in Physics and Math tests by the groups with and without PMS were analyzed by the Mann-Whitney test. The marks of the group PMS in and outside the premenstrual period were evaluated by the signal test. Results: of 4438 questionnaires applied, 29 from students with PMS and 29 from controls were selected. Comparing the medians of the marks obtained by the students from the PMS group in and outside the premenstrual period, there was no significant difference. There was also no significant difference between the marks of the PMS and control groups. Also, when the scores were evaluated, there was no difference in and outside the period, in the PMS group. Conclusion: PMS was not able to modify significantly the students' marks or scores in this study.

7301 downloads Citado 4 vezes em SciELO

Exibindo

itens por página

Página de 1 Próxima

Selecione um ou mais resultados

Todos Ordem alfabética

Resultados

Gráfico comparativo Download CSV

Visualizar estatísticas de

Enviar resultado

E-mail do(s) destinatários*

Utilize ; (ponto e vírgula) para mais de um e-mail.

Enviar por e-mail

Esta página

Registros selecionados

Todos os registros (max. 300)

Alterar remetente, assunto e comentários

Seu email

Assunto

Comentários

Alterar remetente, assunto e comentários

Exportar resultados

Formato de exportação:

RIS (para EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citação

CSV (para Excel, etc)

Exportar:

Esta página

Itens selecionados

Todos os registros (max. 2000)

Mostrar mais

Sem resultados

Não foram encontrados documentos para sua pesquisa

Glossário e ajuda para busca

Você pode enriquecer sua busca de uma forma muito simples. Use os índices de pesquisa combinados com os conectores (AND ou OR) e especifique cada vez mais sua busca.

Por exemplo, se você deseja buscar artigos sobre
casos de dengue no Brasil em 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

Veja abaixo a lista completa de índices de pesquisa que podem ser usados:

Cód. do Índice	Elemento
ti	título do artigo
au	autor
kw	palavras-chave do artigo
subject	assunto (palavras do título, resumo e palavras-chave)
ab	resumo
ta	título abreviado da revista (ex. Cad. Saúde Pública)
journal_title	título completo da revista (ex. Cadernos de Saúde Pública)
la	código do idioma da publicação (ex. pt - Português, es - Espanhol)
type	tipo do documento
pid	identificador da publicação
publication_year	ano de publicação do artigo
sponsor	financiador
aff_country	código do país de afiliação do autor
aff_institution	instituição de afiliação do autor
volume	volume do artigo
issue	número do artigo
elocation	elocation
doi	número DOI
issn	ISSN da revista
in	código da coleção SciELO (ex. scl - Brasil, col - Colômbia)
use_license	código da licença de uso do artigo

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

Todo o conteúdo de www.scielo.org, exceto onde está identificado, está licenciado sob uma Licença Creative Commons.
saiba mais »